Under the US Supreme Court case FTC v. Actavis (2013), antitrust analysis of “reverse settlements” of IP litigations between makers of branded small molecule drugs and generics requires an analysis under the rule of reason. Are there distinct challenges presented by settlements between branded biologics and biosimilars? In a podcast episode of Our Curious Amalgam, titled “Biologically similar but competitively not so? Economic considerations of IP litigation settlements involving biosimilars” Sean Sheridan and Archan Ruparel speak with Anora Wang and Christina Ma on the complexities of negotiating patent settlements involving biosimilars. Listen to this episode to learn about pharmaceutical entry, price erosion, and more.
MFN is rewriting the launch planning playbook: Commercial and market access strategies must integrate to succeed
MFN-related uncertainty is reshaping pharmaceutical launch planning by making pricing, sequencing, and forecasting decisions more interconnected and...